The European Medicines Agency Has Granted Orphan Medicinal Product Designation To Applied Therapeutics' AT-007 (Govorestat) Sorbitol Dehydrogenase (SORD) Deficiency
Portfolio Pulse from Benzinga Newsdesk
The European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation to Applied Therapeutics' AT-007 (Govorestat) for the treatment of Sorbitol Dehydrogenase (SORD) deficiency.
May 25, 2023 | 11:06 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Applied Therapeutics' AT-007 receives Orphan Medicinal Product Designation from the European Medicines Agency, potentially boosting the company's stock.
The EMA's Orphan Medicinal Product Designation for Applied Therapeutics' AT-007 is a positive development for the company, as it provides regulatory support and potential market exclusivity. This news is likely to be seen as a positive catalyst for the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100